Based on the Heron Therapeuti stock forecast from 3 analysts, the average analyst target price for Heron Therapeuti is USD 6.50 over the next 12 months. Heron Therapeuti’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Heron Therapeuti is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Heron Therapeuti’s stock price was USD 1.77. Heron Therapeuti’s stock price has changed by +1.72% over the past week, -9.69% over the past month and +17,803.65% over the last year.
No recent analyst target price found for Heron Therapeuti
No recent average analyst rating found for Heron Therapeuti
Company Overview Heron Therapeuti
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. Read Less
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technolo...Read More
Frequently Asked Questions About Heron Therapeuti (HRTX) Stock
Based on ratings from 3 analysts Heron Therapeuti's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on HRTX's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for HRTX is USD 6.50 over the next 12 months. The maximum analyst target price is USD 9 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on HRTX's stock to indicate if its overvalued.
The last closing price of HRTX's stock was USD 1.77.
The most recent market capitalization for HRTX is USD 0.27B.
Based on targets from 3 analysts, the average taret price for HRTX is projected at USD 6.50 over the next 12 months.
This means that HRTX's stock price may go up by +267.23% over the next 12 months.
We can't find any ETFs which contains Heron Therapeuti's stock.
As per our most recent records Heron Therapeuti has 126 Employees.
Heron Therapeuti's registered address is 4242 Campus Point Court, San Diego, CA, United States, 92121.
You can get more information about it from Heron Therapeuti's website at https://www.herontx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Heron Therapeuti (HRTX) Stock
Based on ratings from 3 analysts Heron Therapeuti's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on HRTX's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for HRTX is USD 6.50 over the next 12 months. The maximum analyst target price is USD 9 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on HRTX's stock to indicate if its overvalued.
The last closing price of HRTX's stock was USD 1.77.
The most recent market capitalization for HRTX is USD 0.27B.
Based on targets from 3 analysts, the average taret price for HRTX is projected at USD 6.50 over the next 12 months.
This means that HRTX's stock price may go up by +267.23% over the next 12 months.
We can't find any ETFs which contains Heron Therapeuti's stock.
As per our most recent records Heron Therapeuti has 126 Employees.
Heron Therapeuti's registered address is 4242 Campus Point Court, San Diego, CA, United States, 92121.
You can get more information about it from Heron Therapeuti's website at https://www.herontx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for HRTX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
